MF remains diagnosis, treatment challenge

New Orleans - Even with fairly recent advances in the testing and treatment of mycosis fungoides, difficulties still remain with the diagnosis of the rare, slowly progressing cutaneous lymphoma, David P. Fivenson, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023

Ruxolitinib Cream Maintains Disease and Symptom Control in Adults and Adolescents With AD

March 19th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

March 19th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

New Data on Investigational Agent for HS Presented at Annual Meeting

March 18th 2023
© 2023 MJH Life Sciences

All rights reserved.